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Abstract DFT calculations for the acid-catalyzed hydroly-
sis of several maleamic acid amide derivatives revealed that
the reaction rate-limiting step is determined on the nature of
the amine leaving group. Further, it was established that
when the amine leaving group was a secondary amine,
acyclovir or cefuroxime moiety the tetrahedral intermediate
formation was the rate-limiting step such as in the cases of
acyclovir ProD 1- ProD 4 and cefuroxime ProD 1- ProD 4.
In addition, the linear correlation between the calculated and
experimental rates provided a credible basis for designing
prodrugs for masking bitter taste of the corresponding pa-
rental drugs which have the potential to release the parent
drug in a sustained release fashion. For example, based on
the DFT calculated rates the predicted t1/2 (a time needed for
50 % of the reactant to be hydrolyzed to products) for
cefuroxime prodrugs, cefuroxime ProD 1- ProD 4, were
12 min, 18 min, 200 min and 123 min, respectively.
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Introduction
Taste, smell, texture and after taste are important factors in
the development of dosage forms. These are important fac-
tor in product preference. Good flavor and texture are found
to significantly affect sells of the product. The major factor
of concern while dealing with pediatric therapies is patient’s
compliance. Pediatric patients tend to become uncoopera-
tive during the administration of oral medication; the most
common reason being the taste of the oral formulation
administered among the children. Most of the antibiotics,
multivitamins and other medicines administered orally have
a bitter taste making them unpleasant for children to
consume.
Organoleptic properties, such as taste, are the major
factors when selecting a certain drug from the generic prod-
ucts available in the market having the same active ingredi-
ent. Nowadays, the pharmaceutical industry is recognizing
the importance of taste masking and a significant number of
techniques have been developed for concealing the objec-
tionable taste [1].
Compounds dissolve in saliva and bind to taste receptors
on the tongue to provide a sweet, salty, bitter, sour, or savory
sensation. Sour and sweet taste receptors are located on the
tip and lateral borders of the tongue respectively. Bitter taste
is sensed by the receptors concentrated on the posterior part
of the tongue and savory taste receptors are distributed in
areas all over the tongue. The sensation is the result of signal
transduction from taste receptors located in areas known as
taste buds [2]. Bitter taste molecules [3–7] are very diverse
in their chemical structure and physicochemical properties
[8, 9]. In humans, bitter taste perception is mediated by 25
G-protein coupled receptors of the hTAS2R gene family
[10–16].
The techniques most commonly used for accomplishing
taste masking include various chemical and physical meth-
ods that prevent the drug substance from interaction with the
taste receptors. The simplest technique involves use of fla-
vor enhancers. Where these methods fail more complex
methodologies are adopted. Several approaches have been
investigated and have resulted in the development of
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efficient techniques for masking a compound’s bitter taste
[17]. All of the developed techniques are based on a phys-
ical modification of the formulation containing the bitter
tastant. Some of these techniques include: (1) coating is
one of the most efficient and commonly used taste masking
techniques[18]; (2) microencapsulation processes used are
commonly based on the principle of solvent extraction or
evaporation [19]; (3) taste masking with flavors, sweeteners,
and amino acids [20]; (4) taste masking with lipophilic
vehicles such as lipids, lecithin, and lecithin- like substances
[21]; (5) sweeteners are generally used in combination with
other taste masking technologies. [22]; (6) taste suppres-
sants and potentiators, such as Linguagen’s bitter blockers
(e.g., adenosine monophosphate), are used for masking the
bitter taste of various compounds by competing with bind-
ing to the G-protein coupled receptor sites (GPCR) [23]; (7)
pH modifiers [24]; (8) adsorbates [25]; (9) resins [26, 27]
and (10) inclusion complexes [28].
Although the mentioned approaches have helped to im-
prove the taste of some drugs formulations, the problem of
the bitter taste of drugs in pediatric and geriatric formula-
tions still creates a serious challenge to pharmacists. Thus,
different strategies should be developed in order to over-
come this serious problem.
The novel chemical approach to be discussed in this
paper involves the design of prodrugs for masking bitter
taste of pharmaceuticals based on intramolecular processes
using density functional theory (DFT) methods [29] and
correlations of experimental and calculated reactions rates.
No enzyme is needed to catalyze the interconversion of a
prodrug to its corresponding drug. The rate of drug release is
controlled by the nature of the linker bound to the drug.
Bitter tastant molecules interact with taste receptors on the
tongue to give bitter sensation. Altering the ability of the
drug to interact with bitter taste receptors could reduce or
eliminate its bitterness. This could be achieved by an appro-
priate modification of the structure and the size of a bitter
compound. Bitter molecules bind to the G-protein coupled
receptor-type T2R on the apical membrane of the taste
receptor cells located in the taste buds. In humans, about
25 different T2R’s are described. Additionally, several
alleles are known and about 1000 different bitter phenotypes
exist in human beings [30, 31].
Due to the large variation of structural features of bitter
tasting molecules, it is difficult to generalize the molecular
requirements for bitterness. Nevertheless, it was reported
that a bitter tastant molecule requires a polar group and a
hydrophobic moiety. A quantitative structure activity rela-
tionship (QSAR) model was developed and has been estab-
lished for the prediction of bitterness of several tastant
analogues. For example, it was reported that the addition
of a pyridinium moiety to an amino acid chain of a variety of
bitter amino acid compounds decreases bitterness, such as in
the case of glycine. Other structural modifications, such as
an increase in the number of amino groups/residues to more
than three and a reduction in the poly-hydroxyl
group/COOH, have been proven to decrease bitterness sig-
nificantly. Moreover, changing the configuration of a bitter
tastant molecule by making isomer analogues was found to
be important for binding affinity to enhance bitterness ago-
nist activity (e.g., L-tryptophan is bitter while D-tryptophan
is sweet) [32].
Unraveling the mechanism of proton transfer between
two oxygens in Menger’s rigid carboxylic amides [33] has
led to the design of prodrugs that mask the bitter taste of
atenolol and dopamine. The role of the linker in these
prodrugs was to block the free amine group in the
corresponding parental drug which is believed to be respon-
sible for the bitterness of the drugs as well as to enable the
release of a drug in a programmable manner [34–39]. For
example, the DFT calculations demonstrated that the effi-
ciency in proton transfer between two oxygens in Kirby’s N-
alkylmaleamic acids and in a proton transfer between two
oxygens in Menger’s rigid carboxylic amides is largely
sensitive to the strain energy difference between the inter-
mediate and the reactant, the distance between the nucleo-
phile and electrophile, and the attack angle by which the
approach step commences. Using the correlation equations
from the plots of the calculated and experimental effective
molarity (EM) values for the above mentioned processes,
the t1/2 (time needed to convert 50 % of a prodrug to its
parental drug) for several prodrugs that mask bitter tastants
was calculated [34–41].
Most of the antibacterial agents used in the market suffer
unpleasant taste and many of them are characterized with
bitter taste. For example, cefuroxime axetil has an extremely
bitter and unpleasant taste which is difficult to mask. This is
a particular problem in geriatric patients who cannot swal-
low whole tablets or when small doses are required. Even
the cefuroxime axetil suspension is difficult for pediatrics to
administer due to its better and unpleasant taste [42–48].
It is believed that the extremely bitter and unpleasant
taste of cefuroxime axetil is due to formation of intermolec-
ular force/s between this drug and the active site of the bitter
taste receptors. The intermolecular bond/s is/are most likely
due to formation of either the hydrogen bond or ionic bond
of the amido group at position 3 and the active site of the
bitter taste receptors.
Cefuroxime axetil is an orally active drug though its
absorption is incomplete. Its bioavailability ranges between
25 to 52 %. The axetil moiety is metabolized to acetalde-
hyde and acetic acid. Peak plasma concentration is reported
about 2 to 3 h after an oral dose. Up to 50 % of cefuroxime
in the circulation is bound to plasma proteins. The plasma
half life is about 70 min and is prolonged in patients with
renal impairments and in neonates. Cefuroxime axetil is
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widely distributed in the body including plural fluid, sputum
bone synovial fluid, and aqueous humour, but only achieves
therapeutic concentration in the CSF when the meninges are
inflamed. It crosses the placenta and has been detected in
breast milk. Cefuroxime is excreted unchanged, by glomer-
ular filtration and renal tubular secretion, and high concen-
tration is achieved in urine [49].
Based on our previously reported DFT calculations and on
experimental data for the acid-catalyzed hydrolysis of amide
acids 1–12 (Scheme 1) [50, 51], four cefuroxime prodrugs are
proposed (Scheme 2). As shown in Scheme 2, the cefuroxime
prodrugs, ProD 1 - ProD 4 molecules are composed of an
amide acid linker, containing a carboxylic acid group (hydro-
philic moiety) and the rest of the antibacterial prodrug mole-
cule (a lipophilic moiety). The combination of hydrophilic and
lipophilic groups provides a prodrug moiety with a potential to
be with a high permeability (a moderate HLB). It is worth
noting, that a hydrophilic lipophylic balance value of the
prodrug molecule will be dependent on the pH of the target
physiologic environment. In the stomach (pH1–2), it is
expected that prodrugs, cefuroxime ProD 1 – ProD 4 will be
in a free carboxylic acid form (a relatively high lipophilicity)
whereas in the blood stream circulation (pH7.4) a carboxylate
anion form (a relatively low lipophilicity) is expected to be
predominant. Our strategy is to prepare cefuroxime ProD 1-
ProD 4 (Scheme 2) as sodium or potassium carboxylates due
to their high stability in neutral aqueous medium. It should be
indicated that compounds 1–12 undergo a relatively fast hy-
drolysis in acidic aqueous medium whereas they are quite
stable at pH7.4.
In this paper, we report a DFT computational study on
intramolecular acid-catalyzed hydrolysis for four different
cefuroxime prodrugs, ProD 1- ProD 4 (Scheme 2). Based
on the calculated and experimental rates for the hydrolysis
of 1–12, the t1/2 values for ProD 1- ProD 4 were evaluated.
The aim of this work was to design various cefuroxime
prodrugs with the potential to be tissue permeable, lack the
bitterness of their parental drug and have the capability to
chemically and not enzymatically undergo hydrolysis in
physiological environment to furnish cefuroxime in a sus-
tain release manner.
Calculations methods
The Becke three-parameter, hybrid functional combined with
the Lee, Yang, and Parr correlation functional, denotedB3LYP,
were employed in the calculations using density functional
theory (DFT). All calculations were carried out using the
quantum chemical package Gaussian-2009 [52]. Calculations
were carried out based on the restricted Hartree-Fock method
[52]. The starting geometries of all calculated molecules were
obtained using the Argus Lab program [53] and were initially
optimized at the HF/6-31G level of theory, followed by opti-
mization at the B3LYP/6-31G(d,p). Total geometry optimiza-
tions included all internal rotations. Second derivatives were
estimated for all 3N-6 geometrical parameters during optimi-
zation. The search for the global minimum structure in each of
the systems studied was accomplished by 360° rotation of the
carboxylic group about the bond C6-C7 (i.e., variation of the
dihedral angle O1/C7/C6/C5, Chart 1), and 360° rotation of the
carbonyl amide group about the C4-C5 bond (i.e., variation of
the dihedral angle O3/C4/C5/C6) in increments of 10° and
calculation of the conformational energies (see Chart 1). For
conservation of computer time, the DFTcalculations for cefur-
oxime ProD 1- ProD 4 were run on molecules by which the
furyl-2-methoxyimino group was replaced with a methyl
group. It is expected that such modification will not affect the
activation energy values for the entities involved in the process.
For systems 1–12, acyclovir ProD 1- ProD 4 and cefuroxime
Prod 1-ProD 4 two types of conformations in particular were
considered: one in which the amide carbonyl is perpendicular
to the carboxyl carbonyl group and another in which it is
planar. An energy minimum (a stable compound or a reactive
intermediate) has no negative vibrational force constant. A
transition state is a saddle point which has only one negative
vibrational force constant [54]. Transition states were located
first by the normal reaction coordinate method [55] where the
enthalpy changes was monitored by stepwise changing the
interatomic distance between two specific atoms. The geome-
try at the highest point on the energy profile was re-optimized
by using the energy gradient method at the B3LYP/6-31G(d,p)
level of theory [52]. The “reaction coordinate method” [55]
was used to calculate the activation energy in all maleamic (4-
amino-4-oxo-2butenoic) acids (Schemes 1 and 2). In this
method, one bond length is constrained for the appropriate
degree of freedom while all other variables are freely opti-
mized. The activation energy values for the approach processes
(the approach of O1 toward C4, Chart 1) were calculated from
the difference in energies of the global minimum structures
(GM) and the derived transition states (tetrahedral intermediate
formation, Scheme 3). Similarly, the activation energies of the
dissociation processes (the breakdown of C4-N9 bond,
Chart 1) were calculated from the difference in energies of
the global minimum structures (GM) and the corresponding
transition states (tetrahedral intermediate breakdown,
Scheme 3). Verification of the desired reactants and products
was accomplished using the “intrinsic coordinate method”
[55]. The transition state structures were verified by their only
negative frequency. Full optimization of the transition states
was accomplished after removing any constrains imposed
while executing the energy profile. The activation energies
obtained from the DFT at B3LYP/6-31G(d,p) level of theory
for all molecules were calculated with and without the inclu-
sion of solvent (water and ether). The calculations with the
incorporation of a solvent were performed using the integral
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equation formalism model of the polarizable continuummodel
(PCM) [56–59]. In this model the cavity is created via a series
of overlapping spheres. The radii type employed was the
united atom topological model on radii optimized for the
PBE0/6-31G(d) level of theory.
Results and discussion
Kirby and coworkers have investigated the structural factors
associated with the high reactivity in the intramolecular
acid-catalyzed hydrolysis of seven maleamic (4-amino-4-
oxo-2butenoic) acids, 1–7 (Scheme 1) [50, 60]. Their find-
ings indicate that the efficiency of the intramolecular hydro-
lysis is remarkably sensitive to the pattern of substitution on
the carbon-carbon double bond and the rate of the hydroly-
sis of the amide acid derivatives studied ranges over more
than ten powers of ten. In addition, their study revealed that
the amide bond cleavage is due to intramolecular nucleo-
philic catalysis by the adjacent carboxylic acid group and
the dissociation of the tetrahedral intermediate is the rate-
limiting step [50]. Later on Kluger studied the intramolecu-
lar hydrolysis mechanism of eight maleamic acids derived
from aliphatic amines of a wide range of basicity [61]. His
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study concluded that the identity of the rate-limiting step is a
function of both the basicity of the leaving group and the
acidity of the solution.
In order to exploit systems 1–12 as prodrug linkers for
cefuroxime and other important drugs we have recently unrav-
eled the mechanism for their acid-catalyzed hydrolysis using
DFT calculation methods. In accordance with the reports by
Kirby [50] and Kluger [61] we have found that the hydrolysis
proceeds by one mechanism, however, the rate-limiting step for
the process was found to be largely dependent on the nature of
the amine leaving group. Two different steps were proposed as
rate-limiting: (1) a step involving the formation of a tetrahedral
intermediate [62], and (2) a step involving tetrahedral interme-
diate dissociation to furnish products (Scheme 3) [55].
Similar to that done for systems 1–12, the DFT calculations
for the acid-catalyzed hydrolysis of cefuroxime prodrugs ProD
1- ProD 4 were directed toward elucidation of the transition
and ground state structures (reactants, intermediates and
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products). Calculations for all entities were conducted in water
and the gas phase. It is expected that the stability of the ground
and transition states will be different in solvent having low
dielectric constant, such as the gas phase and solvent with high
dielectric constant, such as water.
General consideration
The carboxylic acid amide moiety could be engaged in inter-
or intramolecular hydrogen bonding. Therefore the free
energy of the reactant is strongly dependent on its confor-
mation. We were concerned with the identification of the
most stable conformation (global minimum, GM) for each
of cefuroxime ProD 1-ProD 4. The search for the global
minimum structures for all acid amides (cefuroxime ProD
1-ProD 4) was accomplished by 36 rotations of the carboxyl
group about the bond C6-C7 in increments of 10° (i.e.,
variation of the dihedral angle O1/C7/C6/C5, see Chart 1),
and 360° rotation of the carbonyl amide group about the
bond C4-C5 (i.e., variation of the dihedral angle
O3/C4/C5/C6) in increments of 10° and calculation of the
conformational energies (see Chart 1).
In the DFT calculations of the starting geometries in cefur-
oxime ProD 1- ProD 4, two different types of conformations
were considered: one in which the amide carbonyl is perpen-
dicular to the carboxyl group and another in which it is planar
(Chart 1). It was found that the global minimum structures for
cefuroxime ProD 1- ProD 4 all exist in a perpendicular
conformation (see Fig. 1). This is similar to that found for
the global minimum structures of 1–12.
Optimized structures for the molecules involved in the acid-
catalyzed hydrolysis of cefuroxime ProD 1- ProD 4
Global minimum structures (GM)
The global minimum structures for ProD 1GM-ProD 4GM
are shown in Fig. 1. Examination of the calculated geometries
in Fig. 1 indicates that all the reactants exhibit conformations
by which the carboxyl group is engaged intramolecularly in a
hydrogen bond to form a cyclic ring. However, the size of the
ring is dependent on the nature of the substituents on the C-C
double bond of the maleic acid moiety. In addition, the calcu-
lated values for angles α and β in the global minimum
structures were in the range of 121.4–130.8° and 117.8–
123.6°, respectively.
Transition state geometries for the tetrahedral intermediate
formation (TSf)
The calculated DFT optimized structures for the transi-
tion states of the tetrahedral intermediate formation in
ProD 1- ProD 4 (ProD 1TS2- ProD 4TS2) are illus-
trated in Fig. 2. Inspection of the transition state DFT
optimized structures (TSf) indicates that all of them
resemble that of the corresponding reactants (global
minimum structures). Furthermore, the calculated C-O
distance (the distance between the nucleophile O- and
the electrophile C, in all the transition states was
2.30 Å. The angles α and β were quite similar to that
of the corresponding global minimum structures, and
were in the range 118.0–120.5° and 118.1–118.8°, re-
spectively. In addition, the transition state structures
were found to exhibit conformation by which the car-
boxylic group and the neighboring β-lactam carbonyl
oxygen are engaged in intramolecular hydrogen bond to
form six-membered ring. The calculated hydrogen bond
was in the range 1.63−1.64 Å.
Tetrahedral intermediate geometries (INT2)
The optimized structures for the tetrahedral intermediate,
ProD 1INT2- 4INT2, are shown in Fig. 3. Careful exami-
nation of the structures reveals that angles α and β values in
the intermediates are reduced when compared to that of the
corresponding reactants. The α values were found in the
range 108.3–109.6° whereas that for the β were in the range
107.4–109.4°. Furthermore, the angles around the tetrahe-
dral carbon were found to be similar to that of regular
tetrahedral intermediates. Similarly to the transition state
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structures, the intermediate structures were found to exhibit
conformation by which the carboxylic group and the neigh-
boring β-lactam carbonyl oxygen are engaged in intramo-
lecular hydrogen bond to form six-membered ring. The
calculated hydrogen bond was in the range 1.61–1.64 Å.
Mechanistic investigation
The DFT at B3LYP/6-31G(d,p) level of theory kinetic
and thermodynamic properties for cefuroxime ProD 1-
ProD 4 (Scheme 2) were calculated using the quantum
chemical package Gaussian-2009 [52]. The enthalpy and
entropy energy values for all entities involved in the hydroly-
sis global minimum structures (GM), products (P), transition
states (TS) and intermediates, (INT) were calculated in the gas
phase and water. Table S1 lists the energy values for ProD
1GM - ProD 4GM, ProD 1TSf - ProD 4TSf and ProD
1INTf - ProD 4INTf, and Figs. 1, 2 and 3 show their DFT
optimized structures, respectively.
Using the calculated DFT values for the enthalpy and
entropy of the GM and the transition states in the hydrolysis
of cefuroxime ProD 1- ProD 4 the barriers (ΔG‡) for all
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steps described in Scheme 3 were calculated in the gas phase
as well as in a dielectric constant of 78.39 (water). The
activation energy values for those barriers are summarized
in Table 1. Inspection of the ΔG‡ (ΔGf‡, activation energy
for the tetrahedral intermediate formation and ΔGb‡, activa-
tion energy of the tetrahedral intermediate breakdown) val-
ues listed in Table 1 demonstrated that the rate-limiting step
in the acid-catalyzed hydrolysis of cefuroxime ProD 1-
ProD 4 is the intermediate formation (Scheme 3).
In order to evaluate the factors affecting the reaction
rate in cefuroxime prodrugs ProD 1- ProD 4 we have
compared their calculated properties to that previously
calculated for the reactions of 1–12 and acyclovir ProD
1- ProD 4.
Table 1 lists the energy barrier for the intermediate
formation (ΔGf‡) and breakdown (ΔGb‡) for systems 1–
12 and acyclovir ProD 1- ProD 4. Examination of
Table 1 reveals that the rate-limiting step (higher barri-
er) in the gas phase for all systems studied (1–12 and
acyclovir ProD 1–4) is the tetrahedral intermediate for-
mation (the activation energy for the tetrahedral inter-
mediate formation is about 5–30 kcal mol-1 higher than
that for its breakdown). On the other hand, the picture
is somewhat different when the calculations were done
in dielectric constant of 78.39 (water medium). While
for systems 1–9, the rate-limiting step was the break-
down of the tetrahedral intermediate (energy difference
between the breakdown and formation barriers is 3–
8 kcal mol-1) for systems 10–12 and acyclovir ProD
1- ProD 4 the rate-limiting step was found to be the
formation of the tetrahedral intermediate (energy differ-
ence between the formation and break-down barriers is
5–30 kcal mol-1).
Based on the reaction mechanism proposed by
Kirby’s group and our previous calculations [50, 51],
it is expected that polar and apolar solvents will have
different effects on the stabilization of the entities in-
volved in the process. The activation energies for the
Fig. 1 DFT optimized
structures for the global
minimum (GM) in cefuroxime
ProD 1- ProD 4
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tetrahedral intermediate formation process (ΔGf‡) and
the tetrahedral intermediate breakdown process (ΔGb‡)
calculated in water and the gas phase (Table 1) demon-
strate that solvents with low dielectric constants such as
the gas phase tend to shift the equilibrium to the reac-
tants by destabilizing TSf and thus making the approach
as the rate-limiting step whereas solvents with high
dielectric constants such as water interact via dipole-
dipole interactions with the ionic transition state to shift
the equilibrium to the right side. These interactions
stabilize the transition state (TSf) for the tetrahedral
intermediate formation and consequently lower the ap-
proach barrier and thus the reaction rate will be depen-
dent on the tetrahedral intermediate breakdown step.
In order to explore the factor determining the rate-
limiting step, using Allinger’s MM2 method [63] we
have calculated the strain energy values for the reactants
(GM), and intermediates (INT2) in 1–12, aciclovir ProD
1- ProD 4 and cefuroxime ProD 1-ProD 4. The MM2
strain energies (Es) for these structures are tabulated in
Table 1. The calculated Es values were examined for
correlation with the experimental relative rate (log krel)
and DFT calculated activation energy values, (ΔGf‡ and
ΔGb‡) (Table 1). The correlation results demonstrate a
good correlation between the tetrahedral intermediates
strain energy values (Es INT2) in systems 1–7 and the
experimental relative rates (log krel) [50, 51] on one
hand and the activation energies for the tetrahedral
intermediate breakdown (ΔGb‡) on the other hand. The
correlation coefficient values (R) depicted in Fig. 4a and
b were 0.84 and 0.94, respectively. However, in systems
10–12, acyclovir ProD1 –ProD 4 and cefuroxime
ProD1 – ProD4 where the rate-limiting step was the
tetrahedral intermediate formation, the DFT activation
energies were found to be strongly correlated with the
difference in the strain energies of the tetrahedral inter-
mediates and their corresponding global minimum struc-
tures (Es INT-GM) with a correlation coefficient (R) of
0.90 (Fig. 4). Attempts to correlate the strain energies
for the global minimum structures (Es for GM) with the
experimental log krel resulted in a random correlation
with R=0.20.
Figures 4a and b and Table 1 demonstrate that the reaction
rate for systems 1–7 is dependent on the tetrahedral interme-
diate breakdown and its value is largely affected by the strain
energy of the tetrahedral intermediate formed. Systems with
less-strained intermediates such as 2 and 5 undergo hydrolysis
with higher rates than that having more strained intermediates
such as 4. This might be attributed to the fact that the transition
state structures in 1–7 resemble that of the corresponding
intermediates. On the other hand, as shown in Table 1 the acid
catalyzed hydrolysis rates for systems 9–12, acyclovir ProD1-
ProD4 and cefuroxime ProD1-ProD4 are solely dependent
on the tetrahedral intermediate formation step (rate-limiting).
The rate for systems having global minimum and intermediate
structures with close similarity (Es for INT close to Es for
GM) such as system 11 and Cefuroxime ProD 4 is higher than
that for processes bywhich the difference in the strain energies
for their intermediates and the corresponding reactants (Es
(INT-GM) is large such as acyclovir ProD 1 and acyclovir
ProD 4 . This is because less energy is needed to convert
a reactant to tetrahedral intermediate with similar
structures.
Compounds 10–12, acyclovir ProD 1- ProD 4 and
cecfuroxime ProD 1- ProD 4 represent systems with
different leaving groups by which the leaving group
NHMe in 1–9 was replaced with more bulky groups.
In the case where the leaving group is a secondary
amine, NH(CH3)2, or a cefuroxime moiety the
formation-break-down barriers ratio is shifted toward
the formation whereas in the cases where the leaving
group is a primary amine, NHCH3, the amine moiety
has less ability to leave due to the electron-donating
effect of the methyl group. This result is in accordance
with the conclusions drawn by Kluger and Chin [48].
For drawing credibility to the DFT calculations executed
in this study the water calculated B3LYP/6-31G(d,p) free
activation energies for the tetrahedral intermediate break-
down (ΔGBW‡) were correlated with the corresponding ex-
perimental free activation energies (Exp ΔG‡). Strong
correlation was obtained with a correlation coefficient R=
0.97 (Fig. 4).
Fig. 2 DFT optimized structures for the transition state structures
(TSf) in the reactions of cefuroxime ProD 1- ProD 4
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The effective molarities (EM) for the reactions of 1–12,
acyclovir ProD 1- ProD 4 and cefuroxime ProD 1 - ProD 4
The effective molarity (EM) value is commonly used as a
measure for intramolecular efficiency. It is defined as a rate
ratio of the intramolecular reaction and its corresponding inter-
molecular where both reactions are driven by the same mech-
anism. Values in the order of 109–1013 M have been measured
for the EM in intramolecular processes occurring through nu-
cleophilic addition. Whereas for proton transfer processes EM
values of less than 10 M were reported [64, 65].
For obtaining the EM values for the reactions of 1–12 and
cefuroxime ProD 1–4 we have calculated the kinetic and
thermodynamic parameters for their corresponding intermolec-
ular process, Inter (Scheme 4).
Equation 5, derived fromEqs. 1–4, describes the EM term as
a function of the difference in the activation energies of the
intra- and the corresponding intermolecular processes. The
calculated EM values for the reactions of 1–12, acyclovir
ProD 1- ProD 4 and cefuroxime ProD 1- ProD 4 as calculated
by Eq. 5 are listed in Table 1.
EM ¼ kintra kinter= ð1Þ
ΔGzinter ¼ RT ln kinter ð2Þ
ΔGzintra ¼ RT ln kintra ð3Þ
ΔGzintra ΔGzinter ¼ RT ln kintra kinter= ð4Þ
ln EM ¼  ΔGzintra ΔGzinter
 
RT= ð5Þ
Where T is the temperature in Kelvin and R is the gas
constant.
The calculated log EM values in Table 1 were correlated
with the corresponding EM experimental values. The correla-
tion equation with its correlation coefficient is shown in Eq. 6.
Fig. 3 DFT optimized
structures for the tetrahedral
intermediate INT2 (INTf)
structures in the reactions of
ProD 1- ProD 4
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Careful examination of the calculated log EM values listed in
Table 1 demonstrates that 2, 5were the most efficient processes
among 1–9, whereas 4 and 8were the least. The discrepancy in
rates between 2 and 5 on one hand and 4 and 8 on the other
hand might be attributed to strain effects.
log EMcalc ¼ 0:81 log EMexp þ 4:75 R2 ¼ 0:86 ð6Þ
Calculation of the t1/2 values for the acid catalyzed hy-
drolysis of cefuroxime prodrugs ProD 1-ProD 4.
Using Eqs. 7 and 8 obtained from the correlation of log
krel vs. ΔGb‡ and ΔGf‡ vs. ΔGb‡ and the t1/2 value for process
2, t1/2 about 50 min (36), we have calculated the t1/2 values
for cefuroxime ProD 1- ProD 4. The calculated t1/2 values
at pH5 for cefuroxime ProD 1- ProD 4 are 12 min, 18 min,
200 min and 123 min, respectively. It should be indicated
that the t1/2 for the hydrolysis reaction of these prodrugs at
higher pHs such as 6 (intestine) or 7.4 (blood circulation)
will be much higher than the values at pH5.
log krel ¼ 0:44 ΔGzb þ 13:53 R2 ¼ 0:93 ð7Þ
ΔGzf ¼ 1:15 ΔGzb þ 1:11 R2 ¼ 0:95 ð8Þ
Conclusions
The DFT calculations demonstrated that the efficiency of
these processes is largely sensitive to the pattern of substi-
tution on the carbon-carbon double bond and the nature of
the amide N-alkyl group. The reaction rate was found to be
linearly correlated with the strain energy difference between
Table 1 DFT (B3LYP) calculated kinetic and thermodynamic properties for the acid catalyzed hydrolysis of 1–12, acyclovir ProD 1- ProD 4,
cefuroxime ProD 1 – ProD 4 and Inter
System ΔGbGP
‡
(kcal mol-1)
ΔGbW
‡
(kcal mol-1)
ΔGfGP
‡
(kcal mol-1)
ΔGfW
‡
(kcal mol-1)
log krel
[50]
log EM
[50] (Exp)
log EM
(Calc)
Es (INT2)
(kcal mol-1)
Es (GM)
(kcal mol-1)
1 28.08 33.06 33.53 26.10 0 7.724 8.52 20.55 10.16
2 16.42 20.05 27.08 17.90 4.371 15.86 18.08 16.16 10.82
3 24.90 28.42 32.57 24.80 1.494 7.742 11.93 17.32 9.40
4 36.77 38.11 45.37 32.16 −4.377 1.255 4.81 27.89 12.30
5 17.41 23.12 26.87 17.89 2.732 15.190 15.82 19.25 9.18
6 23.92 27.28 32.12 23.87 1.516 6.962 12.76 17.59 5.12
7 25.03 27.55 32.3 24.40 1.648 8.568 12.57 18.55 6.20
8 24.87 30.12 32.37 23.66 – – 6.36 22.34 12.86
9 17.24 15.15 25.94 11.97 – – 21.68 26.92 28.29
10 4.65 24.64 26.19 29.04 – – 11.47 26.92 28.29
11 0.66 19.02 21.07 36.41 – – 6.06 21.56 14.15
12 2.80 8.79 24.27 22.87 – – 16.01 19.78 25.52
Aciclovir
ProD 1
4.93 2.07 32.83 26.46 – – 13.36 24.71 7.13
Aciclovir
ProD 2
8.42 0.66 34.12 31.50 – – 9.66 29.45 32.70
Aciclovir
ProD 3
6.02 2.26 30.53 22.96 – – 15.94 42.27 48.80
Aciclovir
ProD 4
3.44 2.92 34.04 25.73 – – 13.91 31.16 35.70
Cefuroxime
ProD 1
0 5.22 27.25 19.22 – – 18.70 65.66 55.13
Cefuroxime
ProD 2
4.65 3.18 22.45 19.44 – – 18.54 60.72 56.64
Cefuroxime
ProD 3
0.66 0.82 26.14 20.75 – – 17.57 57.98 52.12
Cefuroxime
ProD 4
2.80 0 21.79 20.47 – – 17.77 64.19 60.95
Inter – 44.65 – – – – – – –
B3LYP refers to values calculated by B3LYP/6-31G(d,p) method. ΔG‡ is the calculated activation free energy (kcal mol-1 ). Es refers to strain
energy calculated by Allinger’s MM2 method. GM and INT2 refer to reactant and intermediate 2, respectively. EM = e
-(ΔG‡inter - ΔG‡intra)/RT . BW
and FW refer to tetrahedral intermediate breakdown and tetrahedral intermediate formation calculated in water, respectively. Exp refers to
experimental value. Calc refers to DFT calculated values
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the intermediate and the reactant (Es INT-GM). In addition,
a linear correlation between the calculated and experimental
EM values reinforce the credibility of using DFT methods in
predicting energies as well as rates for reactions of the type
described herein [66–71].
Using the correlation equation obtained from the plot of
the calculated and experimental EM values we have calcu-
lated the t1/2 of four different cefuroxime prodrugs (ProD 1-
ProD 4).
It should be indicated, that although the calculated and
the experimental t1/2 values are comparable the calculation
results need not be taken too literally in absolute terms since
the data of interest are all comparisons.
The strategy to achieve desirable prodrugs of cefuroxime
that are bitterless and capable of releasing cefuroxime in a
controlled manner is: (i) synthesis of the linker and coupling
of the parent drug to the linker using Kirby’s synthetic
procedure [50]; (ii) kinetic studies (in vitro) of the synthe-
sized prodrugs will be performed in physiological environ-
ment, and (iii) for the prodrugs that show satisfactory
properties in the in vitro studies, in vivo pharmacokinetic
studies will be done in order to determine the bioavailability
and the duration of action of the tested prodrugs. In light of
the in vivo pharmacokinetics new prodrugs will be designed
and synthesized.
O
NHCH3
H
H3C
O
CH3HO
Inter
Scheme 4 Schematic representation of the intermolecular process
inter
Fig. 4 a Plot of acid-catalyzed hydrolysis rate (log krel) vs. interme-
diate strain energy (Es INT2) for processes 1–7. b Plot of activation
energy for tetrahedral intermediate breakdown ΔGb‡ vs. intermediate
strain energy (Es INT2) for the reactions of 1–8. c Plot of activation
energy for tetrahedral intermediate formation ΔGf‡ vs. strain energy
difference between intermediate and reactant (Es INT2-GM) in systems
10–12, acyclovir ProD 1- ProD 4 and cefuroxime ProD 1- ProD 4. d
Plot of activation energy for tetrahedral intermediate formation ΔGf‡
vs. activation energy for tetrahedral intermediate breakdown ΔGb‡ in
systems 1–9
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